Try our mobile app
Screener
Company
Price and
change
Revenue Growth
last / hist
EV /
LTM
EBITDA
(p75)
EV/
Sales
EBITDA LTM
/ Revenue
FCF LTM
/ Revenue
Next GAAP report
Year div-d yield
FCF Yield LTM
-52.9%  /
90.4%
35.8x
54.1x
6.5x
19.4%
33.3%
..
0.0%
4.5% 
26.4%  /
58.6%
16.4x
28.4x
4.8x
29.9%
11.4%
..
0.0%
2.1% 
-41.0%  /
55.4%
2.2x
3.7x
0.7x
33.1%
39.7%
..
2.2%
28.6% 
6.4%  /
46.1%
8.4x
8.5x
2x
23.6%
-6.0%
2025-11-08
0.0%
-3.1% 
8.5%  /
30.9%
56.2x
54.3x
11.2x
20.3%
-14.9%
..
1.6%
-1.3% 
-11.3%  /
28.1%
54x
42.7x
14.5x
27.4%
6.6%
..
0.0%
0.5% 
-1.9%  /
24.6%
1.9x
4.3x
0.6x
34.9%
7.6%
2025-08-27
0.0%
8.9% 
46.4%  /
19.8%
26x
37.9x
9.5x
36.8%
15.1%
..
0.9%
1.6% 
-16.7%  /
18.5%
32.8x
27.9x
12.5x
38.5%
26.2%
..
0.8%
2.1% 
-0.5%  /
14.4%
16.9x
19.5x
5.1x
30.7%
27.2%
2025-08-14
1.1%
5.2% 
-8.0%  /
13.8%
4.2x
8.4x
0.8x
20.4%
10.2%
..
0.0%
8.7% 
-21.4%  /
12.6%
16.4x
23.7x
0.8x
4.9%
-5.1%
..
0.0%
-9.0% 
33.3%  /
11.9%
2.2x
4.1x
0.3x
19.4%
13.9%
..
0.0%
21.3% 
-2.6%  /
11.3%
16.8x
24.2x
4.6x
27.8%
7.5%
2025-11-08
0.5%
2.1% 
-17.6%  /
10.2%
17.3x
13.1x
0.7x
4.1%
10.7%
2026-02-05
0.0%
15.5% 
-24.1%  /
5.5%
12.8x
16.4x
2.5x
19.6%
0.6%
2025-11-08
0.0%
0.2% 
8.2%  /
5.3%
21x
27.7x
9.4x
44.7%
-0.9%
2026-02-05
1.2%
-0.1% 
33.5%  /
5.0%
20.2x
19x
6.9x
34.1%
5.6%
..
0.9%
0.8% 
-5.7%  /
4.1%
17.3x
18.4x
1.9x
11.0%
14.6%
2025-11-10
0.0%
7.2% 
59.3%  /
2.4%
>200x
>200x
8.5x
-27.4%
3.5%
2025-08-28
0.0%
0.4% 
0.0%  /
0.0%
>200x
>200x
61x
0.0%
0.0%
..
0.0%
-17.7% 
18.2%  /
-3.6%
28.1x
114.2x
0.7x
2.6%
-1.9%
2025-11-08
0.0%
-2.9% 
-10.7%  /
-5.5%
27.9x
27.4x
6x
21.8%
8.9%
..
0.4%
1.5% 
-70.1%  /
-7.1%
>200x
1.6x
1.2x
-66.2%
-51.2%
2025-08-26
0.0%
-24.5% 
-35.7%  /
-10.7%
>200x
18x
2.1x
-24.4%
-5.8%
2026-02-05
0.0%
-5.6% 
-2.7%  /
-13.7%
>200x
18.5x
2.6x
-18.6%
-3.2%
2026-02-05
0.0%
-0.9% 
-11.7%  /
-17.5%
>200x
6.4x
0.5x
-10.3%
-1.3%
2025-11-10
0.0%
-2.4% 
Trending screeners:
@electric-vehicles
@saas
@cannabis-players
@china
Latin America
India
Dividends
@REITs
@adtech
@airlines
@artificial-intelligence
@auto-parts
@cloud-computing
@crypto
@cybersecurity
@e-commerce
@edtech
@finance-and-technology
@gaming
@internet-of-things
@oil-refining
@real-estate-tech
@renewable-energy
@vaccine-makers

Reviews

2025-08-17
(review)
Weekly results
for USD strategies

US Leaders: +2.0%

Global Commodities: +2.8%

Trending Ideas: +6.8%

Rising Stars: +7.8%

vs S&P500: +0.9%
2025-08-16
#reports #RICK

[RCI Hospitality](https://eninvs.com/all.php?name=RICK) (Restaurants) reported for [2025 q2](https://eninvs.com/press_release.php?source=sec&form_type=10&id=191859)
(2025-07-10, Before Market Open):

- Revenue -6.6% YoY (vs -8.3% in previous quarter and historical rate +24.2%)
- EBITDA margin 18.3% increased compared to 1.3% same period last year
- Net Debt increased by $5 mln over the past reporting period (1.4% of market cap)
- FCF (LTM) +$0 bln (positive), 2.0% of market cap
- EV/EBITDA multiple is 12x compared to historical level (75th percentile) of 17.7x
- EV/Sales multiple is 2.1x

At the opening of the session the share price went down -0.2% vs S&P500 +0.1%
2025-08-16
#reports #VNRX

[VolitionRx Limited](https://eninvs.com/all.php?name=VNRX) (Diagnostics and Research) reported for [2025 q2](https://eninvs.com/press_release.php?source=sec&form_type=10&id=191820)
(2025-08-13, After Market Close):

- Revenue +2.8% YoY (vs +43.0% in previous quarter and historical rate +117.8%)
- EBITDA margin -1485.3% increased compared to -1697.2% same period last year
- Net Debt increased by $4.6 bln since the start of the year (6822.9% of market cap)
- FCF (LTM) -$4.8 bln (negative), 7220.9% of market cap
- EV/Sales multiple is 6.2x

At the opening of the session the share price went up +8.1% vs S&P500 -0.2%
2025-08-16
#reports #INTZ

[Intrusion](https://eninvs.com/all.php?name=INTZ) (Software — Infrastructure) reported for [2025 q2](https://eninvs.com/press_release.php?source=sec&form_type=10&id=191824)
(2025-08-12, After Market Close):

- Revenue +100% YoY (vs +100.0% in previous quarter and historical rate +16.7%)
- EBITDA margin -100.0% has not changed compared to -100.0% same period last year
- Net Debt increased by $2 mln over the past reporting period (71.6% of market cap)
- FCF (LTM) +$0 bln (positive), 143.1% of market cap
- EV/Sales multiple is 0.1x

At the opening of the session the share price went up +2.6% vs S&P500 +0.3%
2025-08-16
#reports #DAN

[Dana](https://eninvs.com/all.php?name=DAN) (Auto Parts) reported for [2025 q2](https://eninvs.com/press_release.php?source=sec&form_type=10&id=191814)
(2025-08-04, Before Market Open):

- Revenue -29.3% YoY (vs -14.0% in previous quarter and historical rate -0.9%)
- EBITDA -57.4% YoY (vs -1.7% in previous quarter and historical rate +0.3%)
- EBITDA margin 4.8% decreased compared to 7.9% same period last year
- Net Debt increased by $340 mln over the past reporting period (12.7% of market cap)
- FCF (LTM) +$1518.1 bln (positive), 56635.1% of market cap
- EV/EBITDA multiple is 11.2x compared to historical level (75th percentile) of 8.1x
- EV/Sales multiple is 0.6x

At the opening of the session the share price went up +1.9% vs S&P500 +0.5%
2025-08-16
#reports #ADES

[Advanced Emissions Solutions](https://eninvs.com/all.php?name=ADES) (Pollution and Treatment Controls) reported for [2025 q2](https://eninvs.com/press_release.php?source=sec&form_type=10&id=191778)
(2023-11-08, After Market Close):

- Revenue +16% YoY (vs +22.7% in previous quarter and historical rate +20.7%)
- EBITDA +50% YoY (vs +200.0% in previous quarter)
- EBITDA margin 10.3% increased compared to 8.0% same period last year
- Net Debt increased by $1 mln over the past reporting period (0.7% of market cap)
- FCF (LTM) -$0 bln (negative), 20.9% of market cap
- EV/EBITDA multiple is 20.1x compared to historical level (75th percentile) of 29.3x
- EV/Sales multiple is 0.8x

At the opening of the session the share price went up +0.5%
2025-08-16
#reports #YMAB

[Y-mAbs Therapeutics](https://eninvs.com/all.php?name=YMAB) (Therapeutic drug developer) reported for [2025 q2](https://eninvs.com/press_release.php?source=sec&form_type=10&id=191744)
(2025-08-07, Before Market Open):

- Revenue -13% YoY (vs +5.0% in previous quarter and historical rate +39.0%)
- EBITDA margin -30.0% increased compared to -43.5% same period last year
- Net Debt increased by $1 mln over the past reporting period (0.3% of market cap)
- FCF (LTM) -$0 bln (negative), 4.5% of market cap
- EV/Sales multiple is 3.7x

2025-08-16
#reports #XBIO

[Xenetic Biosciences](https://eninvs.com/all.php?name=XBIO) (Biotechnology) reported for [2025 q2](https://eninvs.com/press_release.php?source=sec&form_type=10&id=191740)
(2025-08-12, Before Market Open):

- Revenue -18.7% YoY (vs +16.0% in previous quarter and historical rate +61.0%)
- EBITDA margin 68.3% increased compared to -28.9% same period last year
- Net Debt increased by $384 mln over the past reporting period (8706.5% of market cap)
- FCF (LTM) -$2.1 bln (negative), 48407.0% of market cap
- EV/EBITDA multiple is 9.3x compared to historical level (75th percentile) of 4.7x
- EV/Sales multiple is -2x

2025-08-16
#reports #UTMD

[Utah Medical Products](https://eninvs.com/all.php?name=UTMD) (Medical Instruments and Supplies) reported for [2025 q2](https://eninvs.com/press_release.php?source=sec&form_type=10&id=191732)
(2025-05-15, Before Market Open):

- Revenue 0% YoY (vs -9.1% in previous quarter and historical rate +3.0%)
- EBITDA 0% YoY (vs -20.0% in previous quarter and historical rate -4.2%)
- EBITDA margin 40.0% has not changed compared to 40.0% same period last year
- Net Debt increased by $1 mln over the past reporting period (0.5% of market cap)
- FCF (LTM) +$0.3 bln (positive), 149.6% of market cap
- EV/EBITDA multiple is 8.5x compared to historical level (75th percentile) of 12.6x
- EV/Sales multiple is 3.1x

At the opening of the session the share price went up +1.7% vs S&P500 -0.4%
2025-08-16
#reports #URGN

[UroGen Pharma](https://eninvs.com/all.php?name=URGN) (Biotechnology) reported for [2025 q2](https://eninvs.com/press_release.php?source=sec&form_type=10&id=191727)
(2025-08-07, Before Market Open):

- Revenue +9.1% YoY (vs +5.3% in previous quarter and historical rate +18.5%)
- EBITDA margin -170.8% decreased compared to -118.2% same period last year
- Net Debt increased by $40 mln over the past reporting period (4.3% of market cap)
- FCF (LTM) -$0.1 bln (negative), 7.7% of market cap
- EV/Sales multiple is 9.6x

At the opening of the session the share price went down -3.4% vs S&P500 +0.5%
2025-08-16
#reports #TPIC

[TPI Composites](https://eninvs.com/all.php?name=TPIC) (Industrial company) reported for [2025 q2](https://eninvs.com/press_release.php?source=sec&form_type=10&id=191721)
(2025-08-04, After Market Close):

- Revenue -11% YoY (vs +12.4% in previous quarter and historical rate -6.9%)
- EBITDA margin -11.6% decreased compared to -9.7% same period last year
- Net Debt increased by $61 mln over the past reporting period (545.8% of market cap)
- FCF (LTM) +$0 bln (positive), 241.6% of market cap
- EV/Sales multiple is 0.5x

At the opening of the session the share price went up +0.2% vs S&P500 +0.1%
2025-08-16
#reports #SYPR

[Sypris Solutions](https://eninvs.com/all.php?name=SYPR) (Auto Parts) reported for [2025 q2](https://eninvs.com/press_release.php?source=sec&form_type=10&id=191713)
(2025-08-12, Before Market Open):

- Revenue -13.9% YoY (vs -16.7% in previous quarter and historical rate +7.8%)
- EBITDA -150% YoY (vs 0.0% in previous quarter)
- EBITDA margin -3.2% decreased compared to 5.6% same period last year
- Net Debt decreased by $1 mln over the past reporting period (2.4% of market cap)
- FCF (LTM) -$0 bln (negative), 21.2% of market cap
- EV/EBITDA multiple is 10.7x compared to historical level (75th percentile) of 12.3x
- EV/Sales multiple is 0.4x

At the opening of the session the share price went down -1.5% vs S&P500 +0.3%
2025-08-16
#reports #STE

[STERIS](https://eninvs.com/all.php?name=STE) (Medical equipment supplier) reported for [2025 q2](https://eninvs.com/press_release.php?source=sec&form_type=10&id=191710)
(2025-08-06, After Market Close):

- Revenue +8.7% YoY (vs +4.4% in previous quarter and historical rate +5.4%)
- EBITDA +43.1% YoY (vs -1.8% in previous quarter and historical rate +17.3%)
- EBITDA margin 26.2% increased compared to 19.9% same period last year
- Net Debt decreased by $205 mln over the past reporting period (0.8% of market cap)
- FCF (LTM) +$0.1 bln (positive), 0.5% of market cap
- EV/EBITDA multiple is 15.5x compared to historical level (75th percentile) of 25.1x
- EV/Sales multiple is 4.3x

At the opening of the session the share price went up +2.7% vs S&P500 +0.5%
2025-08-16
#reports #SRTS

[Sensus Healthcare](https://eninvs.com/all.php?name=SRTS) (Medical Devices) reported for [2025 q2](https://eninvs.com/press_release.php?source=sec&form_type=10&id=191708)
(2025-08-07, After Market Close):

- Revenue -22.2% YoY (vs -27.3% in previous quarter and historical rate +18.5%)
- EBITDA -200% YoY (vs -200.0% in previous quarter)
- EBITDA margin -28.6% decreased compared to 22.2% same period last year
- Net Debt decreased by $4 mln over the past reporting period (7.3% of market cap)
- FCF (LTM) +$0 bln (positive), 7.3% of market cap
- EV/Sales multiple is 0.9x

At the opening of the session the share price went down -35.7% vs S&P500 +0.2%
2025-08-16
#reports #SEAS

[SeaWorld Entertainment](https://eninvs.com/all.php?name=SEAS) (Theme park owner) reported for [2025 q2](https://eninvs.com/press_release.php?source=sec&form_type=10&id=191704)
(2023-11-08, Before Market Open):

- Revenue -1.6% YoY (vs -3.4% in previous quarter and historical rate +1.0%)
- EBITDA -10.7% YoY (vs -3.3% in previous quarter and historical rate +11.0%)
- EBITDA margin 37.3% decreased compared to 41.2% same period last year
- Net Debt decreased by $122 mln over the past reporting period (4.4% of market cap)
- EV/EBITDA multiple is 8.2x compared to historical level (75th percentile) of 8.7x
- EV/Sales multiple is 2.9x

At the opening of the session the share price went up +1.7%
2025-08-16
#reports #SBH

[Sally Beauty](https://eninvs.com/all.php?name=SBH) (Professional cosmetics supplier ) reported for [2025 q2](https://eninvs.com/press_release.php?source=sec&form_type=10&id=191702)
(2025-08-05, Before Market Open):

- Revenue -1% YoY (vs -2.8% in previous quarter and historical rate -1.3%)
- EBITDA +3% YoY (vs 0.0% in previous quarter and historical rate +0.9%)
- EBITDA margin 11.0% increased compared to 10.6% same period last year
- Net Debt decreased by $32 mln over the past reporting period (2.4% of market cap)
- FCF (LTM) +$0.1 bln (positive), 6.9% of market cap
- EV/EBITDA multiple is 6.8x compared to historical level (75th percentile) of 8x
- EV/Sales multiple is 0.7x

At the opening of the session the share price went up +10.5% vs S&P500 +0.1%
2025-08-16
#reports #RKDA

[Arcadia Biosciences](https://eninvs.com/all.php?name=RKDA) (Agricultural Inputs) reported for [2025 q2](https://eninvs.com/press_release.php?source=sec&form_type=10&id=191697)
(2023-08-10, After Market Close):

- Revenue 0% YoY (vs 0.0% in previous quarter and historical rate -17.4%)
- EBITDA margin -100.0% has not changed compared to -100.0% same period last year
- Net Debt increased by $1 mln over the past reporting period (15.7% of market cap)
- FCF (LTM) -$0 bln (negative), 63.0% of market cap
- EV/EBITDA multiple is 2.4x compared to historical level (75th percentile) of 1x
- EV/Sales multiple is 0.5x

At the opening of the session the share price went up +4.5%
2025-08-16
#reports #RHE

[Regional Health Properties](https://eninvs.com/all.php?name=RHE) (Medical Care Facilities) reported for [2025 q2](https://eninvs.com/press_release.php?source=sec&form_type=10&id=191695)
(2025-04-03):

- Revenue +150% YoY (vs +75.0% in previous quarter and historical rate +16.5%)
- Net Debt decreased by $1 mln over the past reporting period (20377.5% of market cap)
- FCF (LTM) -$0 bln (negative), 122264.8% of market cap
- EV/EBITDA multiple is 34x compared to historical level (75th percentile) of 17.5x
- EV/Sales multiple is 1.3x

2025-08-16
#reports #RGNX

[REGENXBIO](https://eninvs.com/all.php?name=RGNX) (Developer of viral gene therapy) reported for [2025 q2](https://eninvs.com/press_release.php?source=sec&form_type=10&id=191692)
(2025-08-07, Before Market Open):

- Revenue -4.5% YoY (vs +456.3% in previous quarter and historical rate -1.0%)
- EBITDA margin -281.0% decreased compared to -236.4% same period last year
- Net Debt decreased by $58 mln over the past reporting period (12.8% of market cap)
- FCF (LTM) -$0 bln (negative), 3.8% of market cap
- EV/Sales multiple is 1.3x

At the opening of the session the share price went down -2.8% vs S&P500 +0.5%
2025-08-16
#reports #PRPO

[Precipio](https://eninvs.com/all.php?name=PRPO) (Diagnostics and Research) reported for [2025 q2](https://eninvs.com/press_release.php?source=sec&form_type=10&id=191687)
(2023-11-13, After Market Close):

- Revenue +20% YoY (vs +66.7% in previous quarter and historical rate +55.8%)
- EBITDA margin -16.7% increased compared to -20.0% same period last year
- EV/Sales multiple is 17.1x

At the opening of the session the share price went down -7.1%
2025-08-16
#reports #POWI

[Power Integrations](https://eninvs.com/all.php?name=POWI) (Analog integrated circuits manufacturer) reported for [2025 q2](https://eninvs.com/press_release.php?source=sec&form_type=10&id=191685)
(2025-08-06, After Market Close):

- Revenue +9.4% YoY (vs +15.2% in previous quarter and historical rate -12.9%)
- EBITDA -45.5% YoY (vs +40.0% in previous quarter and historical rate -31.0%)
- EBITDA margin 5.2% decreased compared to 10.4% same period last year
- Net Debt increased by $20 mln over the past reporting period (0.8% of market cap)
- FCF (LTM) +$0 bln (positive), 0.9% of market cap
- EV/EBITDA multiple is 45.5x compared to historical level (75th percentile) of 57.4x
- EV/Sales multiple is 5.3x

At the opening of the session the share price went down -14.9% vs S&P500 +0.5%